Fractyl Health Inc. (GUTS) that went public as recently as February this year is currently trading around $3, a significant decline of over 75% from its initial public offering price.
The Lexington, Massachusetts-based Fractyl Health is a metabolic therapeutics company developing treatments for metabolic diseases, including Type 2 Diabetes, or T2D, and obesity.
The company's lead product candidate is Revita DMR System, or Revita, an outpatient procedural therapy designed to durably modify duodenal dysfunction, a major pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.